CN105916521A - 包含人胎盘灌注液细胞、其亚群的组合物及其用途 - Google Patents

包含人胎盘灌注液细胞、其亚群的组合物及其用途 Download PDF

Info

Publication number
CN105916521A
CN105916521A CN201480073194.6A CN201480073194A CN105916521A CN 105916521 A CN105916521 A CN 105916521A CN 201480073194 A CN201480073194 A CN 201480073194A CN 105916521 A CN105916521 A CN 105916521A
Authority
CN
China
Prior art keywords
cells
placental perfusate
cell
compositions
composition comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480073194.6A
Other languages
English (en)
Chinese (zh)
Inventor
乔迪·P·格尼
张小葵
斯泰西·赫布
罗伯特·J·哈黎里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarity Acquisition II LLC
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Priority to CN202110968902.4A priority Critical patent/CN113679740A/zh
Publication of CN105916521A publication Critical patent/CN105916521A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201480073194.6A 2013-11-15 2014-11-14 包含人胎盘灌注液细胞、其亚群的组合物及其用途 Pending CN105916521A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110968902.4A CN113679740A (zh) 2013-11-15 2014-11-14 包含人胎盘灌注液细胞、其亚群的组合物及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361905077P 2013-11-15 2013-11-15
US201361905076P 2013-11-15 2013-11-15
US61/905,077 2013-11-15
US61/905,076 2013-11-15
PCT/US2014/065665 WO2015073800A2 (en) 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110968902.4A Division CN113679740A (zh) 2013-11-15 2014-11-14 包含人胎盘灌注液细胞、其亚群的组合物及其用途

Publications (1)

Publication Number Publication Date
CN105916521A true CN105916521A (zh) 2016-08-31

Family

ID=53058264

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480073194.6A Pending CN105916521A (zh) 2013-11-15 2014-11-14 包含人胎盘灌注液细胞、其亚群的组合物及其用途
CN202110968902.4A Pending CN113679740A (zh) 2013-11-15 2014-11-14 包含人胎盘灌注液细胞、其亚群的组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110968902.4A Pending CN113679740A (zh) 2013-11-15 2014-11-14 包含人胎盘灌注液细胞、其亚群的组合物及其用途

Country Status (11)

Country Link
US (2) US20160279171A1 (enExample)
EP (1) EP3068432A4 (enExample)
JP (4) JP2016537362A (enExample)
KR (3) KR20210121277A (enExample)
CN (2) CN105916521A (enExample)
AU (3) AU2014348454A1 (enExample)
CA (1) CA2930573C (enExample)
MX (2) MX2016006270A (enExample)
RU (1) RU2016123361A (enExample)
WO (1) WO2015073800A2 (enExample)
ZA (1) ZA201603270B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707491B2 (en) * 2016-11-11 2023-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of treating neurodegenerative disorders
CN110621321B (zh) * 2017-03-15 2024-06-21 浩康生物系统公司 用于造血干细胞移植的组合物和方法
KR20210111244A (ko) * 2018-11-30 2021-09-10 셀룰래리티 인코포레이티드 태반-유래 동종이계 car-t 세포 및 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206343A1 (en) * 2007-02-12 2008-08-28 Edinger James W Hepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations
US20080213228A1 (en) * 2006-10-23 2008-09-04 Anthrogenesis Corporation Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations
US20120009271A1 (en) * 2009-03-12 2012-01-12 Medical College Of Georgia Method of disease-induced and receptor-mediated stem cell neuroprotection
US20120034195A1 (en) * 2002-02-13 2012-02-09 Hariri Robert J Placental stem cells derive from post-partum manmalian placenta, and uses and methods of treatment using said cells
WO2012083023A1 (en) * 2010-12-17 2012-06-21 Anthrogenesis Corporation Treatment of spinal cord injury and traumatic brain injury using amnion derived adherent cells
US20120225096A1 (en) * 2005-10-13 2012-09-06 Casper Paludan Immunomodulation using placental stem cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
CA2430989A1 (en) 2000-12-06 2002-06-13 Robert J. Hariri Method of collecting placental stem cells
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
CA2796875A1 (en) * 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP2336300B1 (en) 2001-02-14 2015-07-08 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1743025A4 (en) * 2004-03-29 2007-12-05 Cytomatrix Llc METHOD OF MANUFACTURING REGULATOR T CELLS AND THEIR USE
KR20200123283A (ko) * 2005-12-29 2020-10-28 안트로제네시스 코포레이션 태반 줄기 세포 집단
JP2009521930A (ja) 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞及び第２供給源由来幹細胞の共存培養
CA2642826C (en) * 2006-01-23 2019-01-08 Athersys, Inc. Mapc treatment of brain injuries and diseases
KR101514078B1 (ko) * 2006-05-11 2015-04-22 나오코 다케베 제대혈(臍帶血) 줄기 세포 수집 및 그 사용 방법
EP2164953A4 (en) * 2007-06-18 2010-06-30 Childrens Hosp & Res Ct Oak METHOD OF ISOLATING STAIN AND PRECIPITATING CELLS FROM PLAZENTA
KR20220122774A (ko) 2007-09-26 2022-09-02 셀룰래리티 인코포레이티드 인간 태반 관류액으로부터의 혈관형성 세포
RS53841B1 (sr) * 2007-09-28 2015-06-30 Anthrogenesis Corporation Supresija tumora korišćenjem humanog placentalnog perfuzata i intermedijernih ćelija ubica poreklom iz humane placente
US20100143312A1 (en) * 2008-11-21 2010-06-10 Hariri Robert J Treatment of diseases, disorders or conditions of the lung using placental cells
US20100323446A1 (en) * 2009-06-05 2010-12-23 Jill Renee Barnett Method of collecting placental cells
WO2011008277A2 (en) * 2009-07-14 2011-01-20 Massachusetts Institute Of Technology Hematopoietic stromal progenitor cells and uses thereof
US20110280849A1 (en) * 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
AU2011237747B2 (en) * 2010-04-07 2015-07-23 Celularity Inc. Angiogenesis using placental stem cells
CN103097520B (zh) * 2010-07-13 2017-12-05 人类起源公司 产生自然杀伤细胞的方法
US20120164114A1 (en) * 2010-12-17 2012-06-28 Abbot Stewart Treatment of immune-related diseases and disorders using amnion derived adherent cells
US20120171180A1 (en) * 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising amnion derived adherent cells and platelet-rich plasma
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
AU2013302853A1 (en) 2012-08-13 2015-03-05 Anthrogenesis Corporation Natural killer cells and uses thereof
WO2014063035A2 (en) 2012-10-19 2014-04-24 Anthrogenesis Corporation Treatment of pain using amnion derived adherent cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120034195A1 (en) * 2002-02-13 2012-02-09 Hariri Robert J Placental stem cells derive from post-partum manmalian placenta, and uses and methods of treatment using said cells
US20120225096A1 (en) * 2005-10-13 2012-09-06 Casper Paludan Immunomodulation using placental stem cells
US20080213228A1 (en) * 2006-10-23 2008-09-04 Anthrogenesis Corporation Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations
US20080206343A1 (en) * 2007-02-12 2008-08-28 Edinger James W Hepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations
US20120009271A1 (en) * 2009-03-12 2012-01-12 Medical College Of Georgia Method of disease-induced and receptor-mediated stem cell neuroprotection
WO2012083023A1 (en) * 2010-12-17 2012-06-21 Anthrogenesis Corporation Treatment of spinal cord injury and traumatic brain injury using amnion derived adherent cells

Also Published As

Publication number Publication date
CN113679740A (zh) 2021-11-23
MX2021003799A (es) 2021-06-04
AU2014348454A1 (en) 2016-06-02
AU2022215291A9 (en) 2022-11-24
KR20240023709A (ko) 2024-02-22
WO2015073800A2 (en) 2015-05-21
WO2015073800A8 (en) 2015-12-17
CA2930573A1 (en) 2015-05-21
EP3068432A4 (en) 2017-04-19
CA2930573C (en) 2023-12-05
AU2022215291A1 (en) 2022-09-01
US20160279171A1 (en) 2016-09-29
WO2015073800A3 (en) 2015-07-02
KR20210121277A (ko) 2021-10-07
EP3068432A2 (en) 2016-09-21
MX2016006270A (es) 2016-09-07
KR20160098244A (ko) 2016-08-18
JP2016537362A (ja) 2016-12-01
JP2020019777A (ja) 2020-02-06
ZA201603270B (en) 2022-09-28
AU2020202182A1 (en) 2020-04-16
RU2016123361A (ru) 2017-12-20
US20190117705A1 (en) 2019-04-25
JP2024016037A (ja) 2024-02-06
JP2022020622A (ja) 2022-02-01

Similar Documents

Publication Publication Date Title
Elahi et al. CD71+ erythroid cells in human neonates exhibit immunosuppressive properties and compromise immune response against systemic infection in neonatal mice
JP7483087B2 (ja) 造血幹細胞移植用の組成物および方法
JP2024016037A (ja) ヒト胎盤灌流液細胞、その亜集団を含む組成物、およびそれらの使用
JP6647240B2 (ja) 高活性ｎｋ細胞、およびその利用
US20050118142A1 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
McGuckin et al. Cord blood revelations—The importance of being a first born girl, big, on time and to a young mother!
EP2859092A1 (en) Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying treg cells to produce therapeutic vaccine for treatment of diabetes type 1
US20240408198A1 (en) Therapeutic compositions and methods for allogeneic hematopoietic stem cell transplantation
JP7295810B2 (ja) 移植に適した臍帯細胞画分の選択と使用
Basford et al. The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells
TW202134427A (zh) 含有nk細胞之細胞集團之製造方法
CN102282251A (zh) 用于长期造血种群恢复的方法和组合物
CA3064055A1 (en) Selection and use of umbilical cord cell fractions suitable for transplantation
O’Donoghue Implications of fetal stem cell trafficking in pregnancy
JP2010508854A (ja) 幹細胞移植の後の生着を改善するための方法
Kanold Maternal microchimerism
Yasutake et al. SCID‐repopulating activity of human umbilical cord blood–derived hematopoietic stem and/or progenitor cells in a nonobese diabetic/Shi‐SCID mice serial xenotransplantation model and immune cell activities in vitro: a comparative study of the filter method and the hydroxyethyl starch method
Kanold DEPARTMENT OF CLINICAL SCIENCE, INTERVENTION AND TECHNOLOGY
Peltier et al. Development of a New Third-Party Unit for Adult Stem Cell Transplantation using Clinical-Grade Rejected Cord Blood Units
JP2022533191A (ja) 拡大した幹細胞生成物を使用して、血液悪性腫瘍を有する患者の処置転帰を改善するための組成物および方法
Eckstein et al. Joint Congress DGTI & DGI 2016, 7.-10. September 2016, Nürnberg, Abstracts
Civin et al. Sustained, retransplantable, multilineage engraftment of highly
BR112019024077B1 (pt) Método para preparar uma única unidade de sangue do cordão umbilical, e, artigo de fabricação

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160831